MCID: AMP007
MIFTS: 39

Amphetamine Abuse

Categories: Mental diseases

Aliases & Classifications for Amphetamine Abuse

MalaCards integrated aliases for Amphetamine Abuse:

Name: Amphetamine Abuse 12 55 15
Amphetamine-Related Disorders 44

Classifications:



External Ids:

Disease Ontology 12 DOID:670
ICD9CM 35 305.7
MeSH 44 D019969
UMLS 72 C0154536

Summaries for Amphetamine Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of amphetamines despite negative consequences.

MalaCards based summary : Amphetamine Abuse, also known as amphetamine-related disorders, is related to attention deficit-hyperactivity disorder and premature ejaculation. An important gene associated with Amphetamine Abuse is SLC6A3 (Solute Carrier Family 6 Member 3), and among its related pathways/superpathways are Circadian entrainment and Taste transduction. The drugs Risperidone and Dopamine Antagonists have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are behavior/neurological and cellular

Related Diseases for Amphetamine Abuse

Diseases related to Amphetamine Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 attention deficit-hyperactivity disorder 29.5 SLC6A3 SLC6A2 MAOB HTR1B GRM5
2 premature ejaculation 10.5 SLC6A3 HTR1B
3 alcohol-induced mental disorder 10.4 SLC6A3 NPS
4 alcoholic psychosis 10.4 SLC6A3 NPS
5 oppositional defiant disorder 10.4 SLC6A3 SLC6A2
6 pathological gambling 10.3 SLC6A3 MAOB
7 substance abuse 10.2
8 antisocial personality disorder 10.2 SLC6A3 MAOB HTR1B
9 myocardial infarction 10.2
10 vasculitis 10.2
11 abducens nerve disease 10.1 KANTR IVD
12 mood disorder 10.1 SLC6A2 MAOB HTR1B
13 acute myocardial infarction 10.1
14 postencephalitic parkinson disease 10.1 MAOB KANTR
15 brunner syndrome 10.1 MAOB HTR1B
16 oculogyric crisis 10.1 MAOB KANTR
17 atrial standstill 1 10.0
18 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.0
19 arteriovenous malformation 10.0
20 nervous system disease 10.0 SLC6A3 MAOB KANTR
21 major depressive disorder 10.0 SLC6A3 SLC6A2 HTR1B GRM5
22 neurodermatitis 9.9 NPS KANTR
23 alcohol dependence 9.9
24 cardiac conduction defect 9.9
25 triiodothyronine receptor auxiliary protein 9.9
26 immune deficiency disease 9.9
27 ventricular fibrillation, paroxysmal familial, 1 9.9
28 bacterial sepsis 9.9
29 aphasia 9.9
30 pain agnosia 9.9
31 cardiac arrest 9.9
32 thrombosis 9.9
33 transsexualism 9.9
34 patau syndrome 9.9
35 hepatitis a 9.9
36 cerebritis 9.9
37 superior mesenteric artery syndrome 9.9
38 holoprosencephaly 9.9
39 essential tremor 9.9
40 paraplegia 9.9
41 lymphopenia 9.9
42 acquired immunodeficiency syndrome 9.9
43 cocaine abuse 9.9
44 mucormycosis 9.9
45 intracranial hypertension 9.9
46 hypertrophic cardiomyopathy 9.9
47 chromosomal triplication 9.9
48 tremor 9.9
49 rare surgical neurologic disease 9.9
50 migraine with or without aura 1 9.8 NPS KANTR HTR1B

Graphical network of the top 20 diseases related to Amphetamine Abuse:



Diseases related to Amphetamine Abuse

Symptoms & Phenotypes for Amphetamine Abuse

MGI Mouse Phenotypes related to Amphetamine Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.9 ARC GRM2 GRM5 HTR1B MAOB MAPK14
2 cellular MP:0005384 9.61 GRM2 HTR1B ITK MAOB MAP3K5 MAPK14
3 nervous system MP:0003631 9.32 ARC GRM2 GRM5 MAOB MAPK14 NTS

Drugs & Therapeutics for Amphetamine Abuse

Drugs for Amphetamine Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
2 Dopamine Antagonists Phase 4
3 Antipsychotic Agents Phase 4
4 Anesthetics, Local Phase 4
5 Quetiapine Fumarate Phase 4 111974-72-2
6 Anesthetics Phase 4
7 Vasoconstrictor Agents Phase 4
8
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
9
Amphetamine Approved, Illicit, Investigational Phase 3 300-62-9 5826 3007
10
Mirtazapine Approved Phase 3 61337-67-5, 85650-52-8 4205
11
Histamine Approved, Investigational Phase 3 51-45-6 774
12
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
13
Ethanol Approved Phase 3 64-17-5 702
14
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
15 Sympathomimetics Phase 3
16 Antidepressive Agents Phase 3
17 Central Nervous System Stimulants Phase 3
18 Neurotransmitter Agents Phase 3
19 Adrenergic Agents Phase 3
20 Dopamine Agents Phase 3
21 Peripheral Nervous System Agents Phase 3
22 Neurotransmitter Uptake Inhibitors Phase 3
23 Dopamine Uptake Inhibitors Phase 3
24 Autonomic Agents Phase 3
25 Tranquilizing Agents Phase 3
26 Central Nervous System Depressants Phase 3
27 Serotonin 5-HT2 Receptor Antagonists Phase 3
28 Serotonin Antagonists Phase 3
29 Serotonin Agents Phase 3
30 Psychotropic Drugs Phase 3
31 Dopamine D2 Receptor Antagonists Phase 3
32 Anti-Anxiety Agents Phase 3
33 Adrenergic alpha-Antagonists Phase 3
34 Adrenergic alpha-2 Receptor Antagonists Phase 3
35 Adrenergic Antagonists Phase 3
36 Serotonin 5-HT3 Receptor Antagonists Phase 3
37 Histamine H1 Antagonists Phase 3
38
Histamine Phosphate Phase 3 51-74-1 65513
39 Histamine Antagonists Phase 3
40 Anti-Infective Agents Phase 3
41 Analgesics, Opioid Phase 3
42 Paliperidone Palmitate Phase 3
43 Anti-Bacterial Agents Phase 3
44 Narcotics Phase 3
45 Narcotic Antagonists Phase 3
46
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
47
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
48
Dextroamphetamine Approved, Illicit Phase 1, Phase 2 51-64-9 5826
49
Diethylpropion Approved, Illicit Phase 1, Phase 2 90-84-6, 134-80-5 7029
50
Bupropion Approved Phase 2 34841-39-9, 34911-55-2 444

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse, Part 1 Unknown status NCT00000346 Phase 4
2 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
3 An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence Unknown status NCT02541513 Phase 3 paliparidone
4 Mirtazapine as a Treatment for Co-Occurring Opioid and Amphetamine Type Stimulant Dependence (COATS) in Malaysia Unknown status NCT02541526 Phase 3 Mirtazapine;Placebo
5 An Open-label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence (COATS) Unknown status NCT02541500 Phase 3 Minocycline
6 Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland Completed NCT01100853 Phase 3 VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
7 Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial. Active, not recruiting NCT02774954 Phase 3
8 A Dose Ranging Study of Modafinil for Methamphetamine Dependence Unknown status NCT00630097 Phase 2 modafinil
9 Randomised Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence Unknown status NCT00123370 Phase 2 Modafinil
10 A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP104 in Healthy Adult Volunteers With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104
11 A Double-Blind Placebo- and Active-Controlled, Single-Dose Crossover PD and PK Study to Evaluate the Safety, Tolerability and Abuse Liability of IV Administered NRP104 25 mg and 50 mg in Adult Volunteers With Histories of Stimulant Abuse Completed NCT00247572 Phase 2 NRP104
12 Double-Blind, Placebo-Controlled, Dose Response Trial of Ondansetron for the Treatment of Methamphetamine Dependence. Completed NCT00040053 Phase 2 Ondansetron
13 Bupropion for the Treatment of Methamphetamine Dependence Completed NCT00069251 Phase 2 Bupropion
14 Tyrosine for Methamphetamine Dependence Completed NCT00000322 Phase 2
15 Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM: a 6-month Randomized Controlled Trial With 3 Months of Follow-up Completed NCT01888835 Phase 2 Mirtazapine;Placebo
16 Extended-Release Naltrexone (XR-NTX, VIVITROL) for the Treatment of Actively-Using Methamphetamine-Dependent Men Who Have Sex With Men Completed NCT01449565 Phase 2 Naltrexone;Placebo
17 Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM Completed NCT00856323 Phase 2 Truvada
18 Pharmacogenomics and Medication Development for Methamphetamine Dependence Completed NCT00833443 Phase 2 Bupropion
19 Cannabinoids as a New Intervention for Amphetamine Dependence: A Proof-of-concept Study Withdrawn NCT02952196 Phase 2 drug administration
20 Safety and Tolerability Study of Sublingual Lobeline Unknown status NCT00100074 Phase 1 Lobeline
21 Assessment of Interactions Between IV Methamphetamine and Aripiprazole Unknown status NCT00089440 Phase 1 Aripiprazole
22 Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between IV Methamphetamine and Oral Bupropion Unknown status NCT00040040 Phase 1 Bupropion
23 Assessment of Interactions Between IV Methamphetamine and Reserpine Unknown status NCT00267657 Phase 1 Reserpine
24 Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil Unknown status NCT00265278 Phase 1 Modafinil
25 Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline Unknown status NCT00033072 Phase 1 Selegiline
26 Effects of Stimulant Dependence on Human Striatal Dopamine System Unknown status NCT00000350 Phase 1
27 Abuse Liability and Human Pharmacology of Mephedrone (4-methylmethcathinone,4-MMC) Completed NCT02232789 Phase 1 Mephedrone;3,4-methylenedioxymethamphetamine;Placebo
28 Mephedrone and Alcohol Interactions After Single-dose Administration in Humans Completed NCT02294266 Phase 1 Mephedrone and alcohol;Mephedrone;Alcohol;Placebo
29 Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine) Completed NCT00895804 Phase 1 MDMA;Pindolol
30 Interactive Effects of Doxazosin and 3,4-Methylenedioxymethamphetamine (MDMA) in Healthy Subjects Completed NCT01386177 Phase 1 3,4-Methylenedioxymethamphetamine;Doxazosin;placebo
31 Pharmacological Interaction Between Clonidine and 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) Completed NCT01136278 Phase 1 3,4-Methylenedioxymethamphetamine;Clonidine;placebo
32 Pharmacological Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy): Pharmacodynamics (PD) and Pharmacokinetics (PK) Completed NCT00990067 Phase 1 3,4-Methylenedioxymethamphetamine;Duloxetine;Placebo
33 Pharmacological Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy): Pharmacological Effects and Pharmacokinetics Completed NCT00886886 Phase 1 MDMA;Reboxetine, 8 mg;Placebo
34 A Human Laboratory Assessment of the Safety and Potential Efficacy of Varenicline in Methamphetamine-dependent Volunteers Receiving Methamphetamine Completed NCT00713479 Phase 1 Varenicline, then placebo;Placebo, then varenicline
35 A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence Unknown status NCT01899313
36 Cognitive Correlates of Substance Abuse, Part 2 Unknown status NCT00000351
37 Combination of Psychosocial Intervention and Slow Prosecutions for the Treatment of Methamphetamine Abuse/Dependence Unknown status NCT01273701
38 Development of Virtual Reality-Based Addiction Assessment System for Synthetic Drugs Addiction Unknown status NCT02950376
39 A Double-blind, Placebo-controlled Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence Completed NCT00377299 Citicoline;Placebo
40 The Intervention of Group Therapy: Music in Mood Problems of Female Amphetamine Use Disorder Completed NCT03221283
41 Functional Brain Imaging in Recreational Users of Ecstasy Completed NCT00254306
42 The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus Completed NCT02285556
43 The Repetitive Transcranial Magnetic Stimulation (rTMS) for Amphetamine-type Stimulants Addiction Completed NCT02713815
44 Effects of Carvedilol on the Cardiovascular and Subjective Response to MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") Completed NCT01270672 3,4-Methylenedioxymethamphetamine;carvedilol;placebo
45 Mother vs. Child? Healthcare Worker Perceptions of Conflict Between Maternal Autonomy and Child Health When Providing Care for Pregnant Women Engaging in Problematic Substance Use Completed NCT02797990
46 Investigation of Serotonin Neurotransmission in "Ecstasy" Users Employing Combined Dexfenfluramine Challenge and Positron Emission Tomography: a Functional Probe to Assess MDMA Neurotoxicity Completed NCT01296802 dexfenfluramine
47 The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction Recruiting NCT03318081
48 CEASAR (Computerized Exercise to Alter Stimulant Approach Responses) - Piloting a Novel Intervention to Improve Outcomes in Individuals Suffering From Cocaine or Methamphetamine Use Disorder: A Randomized Controlled Study Recruiting NCT03902405
49 Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward Withdrawn NCT00600145 Mirtazapine

Search NIH Clinical Center for Amphetamine Abuse

Cochrane evidence based reviews: amphetamine-related disorders

Genetic Tests for Amphetamine Abuse

Anatomical Context for Amphetamine Abuse

MalaCards organs/tissues related to Amphetamine Abuse:

41
Brain, Cortex, Prefrontal Cortex, Lung, Skin, Breast, Thyroid

Publications for Amphetamine Abuse

Articles related to Amphetamine Abuse:

(show top 50) (show all 248)
# Title Authors PMID Year
1
Treatment of amphetamine abuse/use disorder: a systematic review of a recent health concern. 38
31228128 2019
2
Relationship Between Lifestyle and Family Functioning Among Family Members of Amphetamine Abusers in Southeast Iran. 38
31162215 2019
3
Development of a Semimechanistic Pharmacokinetic-Pharmacodynamic Model Describing Dextroamphetamine Exposure and Striatal Dopamine Response in Rats and Nonhuman Primates following a Single Dose of Dextroamphetamine. 38
30733244 2019
4
Inhibitory control failures and blunted cortisol response to psychosocial stress in amphetamine consumers after 6 months of abstinence. 38
31007690 2019
5
Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. 38
31133886 2019
6
Conditions and Factors Associated With Spontaneous Coronary Artery Dissection (from a National Population-Based Cohort Study). 38
30477805 2019
7
Amphetamine availability predicts amphetamine-related mental health admissions: A time series analysis. 38
29551076 2018
8
An unsuspected role for organic cation transporter 3 in the actions of amphetamine. 38
29773909 2018
9
Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats. 38
29528663 2018
10
Methamphetamine-Induced Cardiomyopathy (MACM) in a Middle-Aged Man; a Case Report. 38
29503834 2018
11
Tracing methamphetamine and amphetamine sources in wastewater and receiving waters via concentration and enantiomeric profiling. 38
28551534 2017
12
Recreational Marijuana Use and Acute Myocardial Infarction: Insights from Nationwide Inpatient Sample in the United States. 38
29312837 2017
13
[Amphetamine abuse is a possible cause of pontine haemorrhage]. 38
29084616 2017
14
Tamoxifen and amphetamine abuse: Are there therapeutic possibilities? 38
27585851 2017
15
Cardiovascular Complications of Acute Amphetamine Abuse: Cross-sectional study. 38
28417026 2017
16
[Prevalence and Therapy of Crystal Methamphetamine Dependence]. 38
28235211 2017
17
Acceleration of cardiovascular-biological age by amphetamine exposure is a power function of chronological age. 38
28243315 2017
18
Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C. 38
27647375 2016
19
A Case of Mania Presenting with Hypersexual Behavior and Gender Dysphoria that Resolved with Valproic Acid. 38
27994833 2016
20
Clinical Characteristics and Outcomes of Patients with Amphetamine-Associated Cardiomyopathy in South Auckland, New Zealand. 38
27185546 2016
21
Facial movement disorder and dopamine imaging in a patient with amphetamine abuse. 38
27502592 2016
22
PKCβ Inhibitors Attenuate Amphetamine-Stimulated Dopamine Efflux. 38
26996926 2016
23
D1 receptor-mediated inhibition of medial prefrontal cortex neurons is disrupted in adult rats exposed to amphetamine in adolescence. 38
26946269 2016
24
The prevalence and clinical features of amphetamine-induced obsessive compulsive disorder. 38
26811120 2016
25
Extended Detection of Amphetamine and Methamphetamine in Oral Fluid. 38
26402425 2016
26
Patterns of drug abuse among drug users with regular and irregular attendance for treatment as detected by comprehensive UHPLC-HR-TOF-MS. 38
26017246 2016
27
Amphetamine Abuse Related Acute Myocardial Infarction. 38
26998366 2016
28
Amphetamine sensitization in mice is sufficient to produce both manic- and depressive-related behaviors as well as changes in the functional connectivity of corticolimbic structures. 38
25959066 2015
29
[The complex of neurological symptoms of substance abuse]. 38
26829868 2015
30
Amphetamine abuse as a rare cause of recurrent LVAD pump thrombosis. 38
25545600 2015
31
Effects of anabolic-androgens on brain reward function. 38
26379484 2015
32
Gabapentin Therapy in Psychiatric Disorders: A Systematic Review. 38
26835178 2015
33
Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. 38
25479916 2015
34
Superior Mesenteric Artery Syndrome Associated with Rapid Weight Loss Attributed to Amphetamine Abuse. 38
26351593 2015
35
[Amphetamine abuse and drug interactions]. 38
25394841 2014
36
Digital holographic microscopy discriminates sex differences in medial prefrontal cortex GABA neurons following amphetamine sensitization. 38
24999221 2014
37
c-MRI findings after crystal meth abuse. 38
25026102 2014
38
The effects of paradoxical sleep deprivation on amphetamine-induced behavioral sensitization in adult and adolescent mice. 38
24844977 2014
39
Amphetamine-related disorders in psychiatric emergency service. 38
24462022 2014
40
Factors associated with buprenorphine compared to amphetamine abuse among clients seeking treatment in Finland. 38
24560129 2014
41
Course and moderators of emotional eating in anorectic and bulimic patients: a follow-up study. 38
24854803 2014
42
Extreme Procalcitonin Elevation without Proven Bacterial Infection Related to Amphetamine Abuse. 38
24826347 2014
43
A rare case of diffuse alveolar hemorrhage following oral amphetamine intake. 38
24765773 2014
44
Negative priming in amphetamine psychosis. 38
23773294 2013
45
Androgenic anabolic steroid, cocaine and amphetamine abuse and adverse cardiovascular effects. 38
24719633 2013
46
Efficacy of psychostimulant drugs for amphetamine abuse or dependence. 38
23996457 2013
47
The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. 38
23623810 2013
48
An unusual case of silent acute ST-elevation myocardial infarction following amphetamine use. 38
24353688 2013
49
Exploring the Spread of Methamphetamine Problems within California, 1980 to 2006. 38
23750069 2013
50
Spatial-temporal disease mapping of illicit drug abuse or dependence in the presence of misaligned ZIP codes. 38
23898219 2013

Variations for Amphetamine Abuse

Expression for Amphetamine Abuse

Search GEO for disease gene expression data for Amphetamine Abuse.

Pathways for Amphetamine Abuse

GO Terms for Amphetamine Abuse

Cellular components related to Amphetamine Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.63 SLC6A3 SLC6A2 SLC22A3 HTR1B GRM5 GRM2
2 postsynaptic density membrane GO:0098839 8.96 GRM5 ARC
3 neuron projection GO:0043005 8.92 SLC6A3 SLC6A2 GRM5 GRM2

Biological processes related to Amphetamine Abuse according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.73 SLC6A3 SLC6A2 MAOB HTR1B
2 chemical synaptic transmission GO:0007268 9.71 SLC6A2 HTR1B GRM5 GRM2
3 response to ethanol GO:0045471 9.65 SLC6A3 MAOB HTR1B
4 regulation of synaptic transmission, glutamatergic GO:0051966 9.51 GRM5 GRM2
5 positive regulation of myoblast differentiation GO:0045663 9.49 MAPK14 MAP3K5
6 G protein-coupled glutamate receptor signaling pathway GO:0007216 9.46 GRM5 GRM2
7 dopamine catabolic process GO:0042420 9.37 SLC6A3 MAOB
8 p38MAPK cascade GO:0038066 9.32 MAPK14 MAP3K5
9 dopamine transport GO:0015872 9.26 SLC6A3 SLC22A3
10 negative regulation of serotonin secretion GO:0014063 9.16 MAOB HTR1B
11 dopamine uptake GO:0090494 8.96 SLC6A3 SLC22A3
12 monoamine transport GO:0015844 8.8 SLC6A3 SLC6A2 SLC22A3

Molecular functions related to Amphetamine Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutamate receptor activity GO:0008066 9.26 GRM5 GRM2
2 neurotransmitter:sodium symporter activity GO:0005328 9.16 SLC6A3 SLC6A2
3 monoamine transmembrane transporter activity GO:0008504 8.96 SLC6A3 SLC6A2
4 dopamine:sodium symporter activity GO:0005330 8.8 SLC6A3 SLC6A2 SLC22A3

Sources for Amphetamine Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....